Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning...

Area of Science:

• Neuroscience
• Pediatric Psychiatry
• Pharmacology

Background:

• Pervasive developmental disorders (PDDs) often co-occur with attention-deficit/hyperactivity disorder (ADHD) symptoms.
• Limited research exists on pharmacological interventions for ADHD in this population.

Purpose of the Study:

• To evaluate the efficacy of atomoxetine for ADHD symptoms in children diagnosed with PDDs.
• To assess the tolerability and side effects of atomoxetine in this specific pediatric group.

Main Methods:

• An 8-week, open-label, prospective study involving 16 children and adolescents with PDDs (autistic disorder, Asperger's disorder, PDD-NOS).
• Participants received atomoxetine at a target dose of 1.2-1.4 mg/kg/day.
• Standardized efficacy and tolerability assessments were conducted regularly.

Main Results:

• 75% of participants showed significant improvement in ADHD symptoms (Clinical Global Impressions-Improvement scale).
• Atomoxetine demonstrated notable effect sizes (1.0-1.9) in reducing ADHD symptoms, irritability, social withdrawal, stereotypy, and repetitive speech.
• The medication was generally well-tolerated, with two participants discontinuing due to irritability. A mean weight decrease of 0.8 kg was observed.

Conclusions:

• Atomoxetine appears to be a potentially effective treatment for ADHD symptoms in children with PDDs.
• Further investigation through placebo-controlled trials is essential to validate these preliminary findings and establish definitive efficacy.